Apologies if this has been already posted, but I just noticed that the details of the EFS are now on clinicaltrials.gov so this is the official info.
15 patients as expected. The trial duration for the primary and secondary endpoints is only 30 days, which is fantastic and fits into the expectation of the pivotal trial starting enrollment early next year. The primary endpoints are successful implantation of the device and no death or stroke within 30 days. Secondary endpoints look at more details.
As expected, the trial will be run by Dr Reardon in Houston, who is very familiar with the DurAVR and ADAPT. Good to see another box being ticked and 15 folks getting the chance to undergo what should be life-changing procedures.
https://clinicaltrials.gov/ct2/show/NCT05712161?term=DurAVR&draw=2&rank=1
- Forums
- ASX - By Stock
- AVR
- EFS details posted to official US government site
EFS details posted to official US government site
-
- There are more pages in this discussion • 55 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVR (ASX) to my watchlist
(20min delay)
|
|||||
Last
$11.93 |
Change
-0.290(2.37%) |
Mkt cap ! $252.1M |
Open | High | Low | Value | Volume |
$12.20 | $12.22 | $11.21 | $199.1K | 17.01K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 577 | $11.59 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$11.93 | 131 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 577 | 11.590 |
1 | 890 | 11.550 |
2 | 1080 | 11.500 |
1 | 400 | 11.360 |
1 | 500 | 11.200 |
Price($) | Vol. | No. |
---|---|---|
11.930 | 131 | 1 |
12.250 | 250 | 1 |
12.500 | 1445 | 2 |
12.750 | 3000 | 1 |
12.850 | 1000 | 1 |
Last trade - 16.10pm 21/10/2024 (20 minute delay) ? |
Featured News
AVR (ASX) Chart |
The Watchlist
LGP
LITTLE GREEN PHARMA LTD
Paul Long, Chief Executive Officer
Paul Long
Chief Executive Officer
SPONSORED BY The Market Online